Charles River to acquire Vigene Biosciences for $293M

By The Science Advisory Board staff writers

May 17, 2021 -- Charles River Laboratories has entered into an agreement to acquire Vigene Biosciences, a U.S-based gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.

In addition to the initial purchase prices, the transaction also includes contingent additional payments of up to $57.5 million based on future performance. The transaction is expected to close in the beginning of the third quarter of 2021.

The acquisition will enhance Charles River's gene therapy capabilities within the cell and gene therapy CDMO sector, the firm said.

Vigene's expertise in adeno-associated virus (AAV) current good manufacturing practice (cGMP) production as well as for other major viral vectors, including lentivirus, will expand Charles River's CDMO capabilities for viral vectors and plasmid DNA.

Vigene also complements Charles River's existing nonclinical development and manufacturing portfolio. Specifically, Vigene will support Charles River's U.S.-based cell therapy production capabilities and help establish an end-to-end, gene-modified cell therapy solution.

Charles River Laboratories shows strong revenue, earnings gains in Q1
Sales gains across all three of its business segments helped drive Charles River Laboratories to a 16.6% increase in revenue in its 2021 first quarter.
Charles River to provide clients with Valence AI tech
Charles River Laboratories and Valence Discovery have formed a strategic partnership to provide clients with access to Valence's artificial intelligence...
Charles River acquires Retrogenix for $48M
Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix.
Charles River to pay $875M to buy Cognate BioServices
Charles River Laboratories has signed a deal to pay about $875 million in cash to acquire cell and gene manufacturer Cognate BioServices.
Charles River, Cypre collaborate on in vitro services
Charles River Laboratories is joining forces with Cypre to advance the understanding of the tumor microenvironment and predict therapeutic efficacy. Charles...
Charles River Laboratories acquires Distributed Bio
Charles River Laboratories has acquired Silicon Valley-based antibody drug discovery firm Distributed Bio for $83 million in cash.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter